Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of sorfequiline-containing regimens for newly diagnosed drug-sensitive pulmonary tuberculosis
PACTR202605489583542Phase 2Not yet recruiting
- Sponsor
- TB Alliance
- Start
- May 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of sorfequiline, pretomanid and linezolid in Tuberculosis (TB) and pulmonary tuberculosis (TB) (2 arms), sponsored by TB Alliance. Primary endpoint: Safety and tolerability through 17 weeks of treatment. Planned start May 2026; status: not yet recruiting.
02
Drugs
sorfequilinepretomanidlinezolid
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202605489583542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605489583542.